Platelet CLEC-2 and podoplanin in cancer metastasis

Kate L Lowe, Leyre Navarro Nunez, Stephen P Watson, Steve Watson

Research output: Contribution to journalArticlepeer-review

70 Citations (Scopus)


It has long been recognised that the function of platelets in health and disease span far beyond their roles in haemostasis and thrombosis. The observation that tumour cells induce platelet aggregation was followed by extensive experimental evidence linking platelets to cancer progression. Aggregated platelets coat tumour cells during their transit through the bloodstream and mediate adherence to vascular endothelium, protection from shear stresses, evasion from immune molecules, and release of an array of bioactive molecules that facilitate tumour cell extravasation and growth at metastatic sites. The sialyated membrane glycoprotein podoplanin is found on the leading edge of tumour cells and is thought to influence their migratory and invasive properties. Podoplanin elicits powerful platelet aggregation and is the endogenous ligand for the platelet C-type lectin receptor, CLEC-2, which itself regulates podoplanin signalling. Here, the bidirectional relationship between CLEC-2 and podoplanin is described and considered in the context of tumour growth and metastasis.
Original languageEnglish
Pages (from-to)S30-7
JournalThrombosis Research
Volume129 Suppl 1
Publication statusPublished - 2012


Dive into the research topics of 'Platelet CLEC-2 and podoplanin in cancer metastasis'. Together they form a unique fingerprint.

Cite this